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Abstract: Three ferroquine (FQ) derivatives, closely mimicking the antimalarial drug 
hydroxychloroquine (HCQ) have been prepared. Whereas these organometallic compounds provide the 
expected reduced cytotoxic effects compared to FQ, they inhibit in vitro growth of Plasmodium 
falciparum far better than chloroquine (CQ). Moreover, this new class of bioorganometallic compounds 
exert antiviral effects with some selectivity towards SARS-CoV infection. These new drugs may offer 
an interesting alternative for Asia where SARS originated and malaria has remained endemic. 
Keywords: Bioorganometallics, Ferroquine, Malaria, SARS-CoV 
 
Introduction 
Malaria is a major international public health problem, causing 300-500 million infections worldwide 
and a death toll of approximately 1.1-2.7 million annually.
1
 Plasmodium falciparum accounts for most 
of the mortality, and its resistance to antimalarial drugs has developed in many regions of the world.
2,3
 
Chemists and biologists have combined their efforts in an attempt to find efficient and affordable drugs 
for the developing countries. Several approaches have been investigated
4,5
 and new projects at various 
stages of development have emerged.
6
 Besides, apart from these classical organic schemes, an atypical 
strategy based on modification of the old drug chloroquine (CQ) by a ferrocenyl fragment led to the 
identification of FQ (Figure 1).
7,8
 
Ferroquine has been shown to be remarkably effective against CQ-resistant P. falciparum.
7
 Moreover, 
no observable immunotoxic effects were detected in naïve and infected young rats.
9
 The mode of action 
of FQ is believed to be similar to that of CQ and probably involves hematin as the drug target and 
inhibition of hemozoin formation.
10 
A recent study of FQ metabolism in animal and human hepatic 
models revealed similarities to that of CQ.
11
 One notable difference is that while the two main CQ 
metabolites are not active against CQ-resistant P. falciparum, FQ metabolites still exhibited a 
significant activity. Also, it is important to note that the close parent of CQ, hydroxychloroquine (HCQ) 
 3 
was reported to be less toxic than CQ, but was found inactive on CQ-resistant P. falciparum.
12
 On the 
other hand, aminoquinoline-based antimalarials like CQ or mefloquine (MF) also had antiviral efficacy 
and showed a synergistic action with HIV protease
 
inhibitors (PIs).
13-16
 CQ has been reported to possess 
strong antiviral effects on the severe acute respiratory syndrome (SARS) causative agent.
17
 SARS is a 
febrile respiratory illness caused by a novel coronavirus, SARS-associated coronavirus (SARS-CoV),
18-
21
 which emerged in southern China in November 2002. SARS-CoV is believed to be of zoonotic origin. 
Although several animal species (e.g., civet) sold for human consumption in markets in southern China 
have demonstrated evidence of SARS-CoV infection, the wild reservoir of SARS-CoV is still 
unknown.
22
 As of today, no efficacious therapy is available, although many candidate anti-SARS-CoV 
agents have been identified.
17,23,24,25
 
Encouraged by the strong antimalarial activity of FQ on CQ-resistant clones and field isolates, we aimed 
to study if hydroxyferroquine (HFQ) might retain a significant activity against P. falciparum and a set 
of different viruses. A series of new bioorganometallics (Figure 1) was designed and synthesized in an 
effort to combine specific properties of both drugs: an assumed lower toxicity of HFQ associated with a 
restored antimalarial activity against CQ-resistant parasites. Such molecules would be an interesting 
alternative to ferroquine for malaria therapy and provide an additional interest in areas where malaria 
and viruses infection co-exist. 
 
Results and Discussion 
Synthesis. Like FQ, the hydroxyl FQ derivatives 2-4 can be synthesized easily from inexpensive 
starting materials.
7
 Quaternerization of the terminal nitrogen atom of FQ was performed with methyl 
iodide in acetone at room temperature (Scheme 1). The resulting quaternary ammonium is the leaving 
group that was displaced by the appropriate amino-alcohol in acetonitrile under reflux. This nucleophilic 
substitution afforded products 2, 3 and 4 in 46%, 46% and 51% yield, respectively. 
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Antimalarial activity. Metallocenes 2-4 were evaluated in vitro against the CQ-sensitive HB3 strain 
and the CQ-resistant W2 strain of P. falciparum (Table 1). The three hydroxy-derivatives 2-4 were more 
active than CQ against the resistant strain. Among these amino-alcohol derivatives, the activity 
increased from the unsubstituted 2 to the N-ethyl-substituted 4. Note also that the most active product 4 
was even more active than mefloquine and only slightly less active than FQ against both P. falciparum 
strains. 
The screening performed on 25 Cambodian field isolates confirmed the high potent antimalarial activity 
of the novel metallocenic compound 4 against P. falciparum (Table 2). Hydroxyferroquine derivative 4 
was much more active than CQ and only slightly less active than FQ and MF. Although no cross 
resistance was found with MF (r
2
 = 0.021), Q (r
2
 = 0.00005) and ARS (r
2
 = 0. 0732), a slight cross 
response was observed with CQ (r
2
 = 0.32). Metallocene 4 showed almost the same level of activity as 
that of FQ. As expected, a high correlation (r
2 
= 0.7129) between the IC50 of FQ and 4 was noted within 
the isolates tested. This suggests that the two compounds have a similar mode of action and/or uptake by 
the parasite. 
Studies concerning toxicity and antimalarial activity of HCQ are controversial and HCQ appears as 
lacking activity against CQ resistant strains of P. falciparum.
12
 Our goal, on the basis of the high 
activity of FQ, was to synthesize a potentially less toxic molecule which would exhibit significant 
antimalarial activity. Among the three hydroxyferroquine-type derivatives synthesized, the results 
obtained for both laboratory clones and field isolates confirmed the strong antimalarial activity of 
compound 4 which is only 1.5 fold less active than FQ against all strains and isolates of P. falciparum 
tested and much more active than CQ (6 fold). This product is the most lipophilic of the three 
compounds synthesized, and the results observed are in accordance with the hypothesis already 
proposed to explain the strong activity of FQ against P. falciparum CQ resistant strains.
10
 Moreover, the 
mechanism of action of the hydroxyferroquine derivatives is probably multifactorial, and involves 
pharmacokinetic parameters. Indeed, oxidative metabolization of tertiary amines like CQ,
26
 HCQ,
27
 and 
FQ
11
 occurs via the cytochrome P-450 system. The main metabolites are generated by side-chain de-
 5 
alkylation leading first to the monodesalkyl and then to the didesalkyl derivatives. The 
biotransformation of FQ has been recently studied in vitro in animal and human models.
11
 Even if 
mono-N-desmethyl- and di-N,N-desmethyl-FQ showed a decreased in vitro activity compared to the 
parent molecule, they remained more active than CQ on P. falciparum CQ-resistant strains.
11,28
 It is 
notably that the metabolites of CQ showed no activity against CQ-resistant strains. The dramatic 
activity of FQ metabolites against CQ-resistant P. falciparum parasites growth enables us to expect a 
long-acting antimalarial activity during chemotherapy of malaria. Oxidative pathways should mediate 
the de-alkylation of bioorganometallics 3 and 4 as previously shown for HCQ
27
 and FQ
11
 (Scheme 2). 
The loss of the ethanol fragment generates the secondary amine 2. The other C-N cleavage generates the 
active mono-N-desmethyl- (dMFQ)
11
 and mono-N-desethyl-FQ (dEFQ)
28
, respectively. By comparison 
with HCQ and FQ, it is tempting to suggest that during a clinical use of metallocenes 3 and 4, formation 
of these active metabolites may occur and participate in the global activity of the parent products. These 
results, together with the fact that compound 4 was five fold less toxic than FQ (see Table 1 and 2 in 
Supporting Information) indicate that bioorganometallics 4 can be considered as a promising alternative 
to FQ for chemotherapy of CQ-resistant malaria. 
Antiviral activity. CQ, HCQ and the metallocenes (FQ and 2-4) were also tested against HIV-1. CQ 
and compound 3 exhibited some activity against HIV-1 with a selectivity index of 3 and 6, respectively 
(Table 3).  
The mechanism of the anti-HIV activity of CQ and HCQ is still not fully understood. But it has been 
linked with the viral entry and related to inhibition of HIV surface envelope glycoprotein gp120. Indeed, 
these compounds are supposed to increase endosomal pH and alter enzymes required for gp120 
production.
14,24
 Based on their chemical structures, hydroxyferroquine derivatives 2-4 might target the 
complex entry process in a similar manner. 
Whereas CQ has been shown to inhibit SARS-CoV replication in vitro, the mode of action of this 
compound is currently still unknown.
17
 In this context, the metallocenic compounds 2-4 were evaluated 
for their activity against feline and human (SARS) coronavirus (Table 4) and compared to their parent 
 6 
drugs, CQ, HCQ and FQ. All compounds, except for HCQ, were effective inhibitors of SARS-CoV 
replication in Vero cells within the 1-10 µM concentration range. Compounds 3, 4, FQ and CQ 
exhibited a selectivity index of approximately 15. These data confirm the anti-SARS-CoV activity noted 
previously with CQ.
17,25,29
 In fact, CQ had been quoted as potentially active against SARS-CoV.
24
 The 
current data supports this hypothesis and extend the anti-SARS-CoV potential further to CQ derivatives 
such as, in particular, the metallocenes FQ, 3 and 4. CQ, HCQ, FQ and compounds 2-4 were evaluated 
against parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, 
respiratory syncytial virus, herpes simplex virus-1 (HSV-1; KOS), herpes simplex virus-2 (HSV-2; G), 
vaccinia virus, vesicular stomatitis virus, herpes simplex virus-1 (TK
-
KOS ACV) and influenza A virus 
(H3N2). Unfortunately, no significant activity was noted (SI Table 1, 2, 3 and 4). This indicates that 
these compounds present a higher specificity for HIV and SARS-CoV viruses. 
 
Our results showed that HFQ derivatives appear as promising new antimalarial molecules, since they 
are active with their potential metabolites against CQ-resistant P. falciparum. Moreover, we showed that 
these drugs have anti-HIV and anti-SARS-CoV activities. These findings highlighted the potential 
interest of metallocenes FQ, 3 and 4 use in all countries where malaria coinfection with HIV and SARS 
viruses will occur. 
 
Experimental section 
Chemistry. Nuclear magnetic resonance (
1
H and 
13
C NMR) spectra were recorded at ambient 
temperature on a Bruker AC 300 spectrometer and TMS was used as an internal standard. 
1
H NMR 
analyses were obtained at 300 MHz (s: singlet, d: doublet, t: triplet, dd: double doublet, m: multiplet); 
whereas 
13
C NMR analyses were obtained at 75.4 MHz. The chemical shifts (δ) are given in parts per 
million relative to TMS (δ = 0.00). Diverse solvents were used in the determination of spectra for 
different compounds. Mass spectra were recorded by mean of a Waters Micromass Quattro II triple 
quadrupole LC mass spectrometer equipped with electrospray ionization (ESI) and atmospheric pressure 
chemical ionization (APCI) sources. Melting points were determined by a Kopfler and are uncorrected. 
Column chromatography, carried out on silica gel (Merck Kieselgel 60) was used in purification of 
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samples. Reactions were monitored by thin-layer chromatography (TLC) using coated silica gel plates, 
detection by an ultra-violet lamp. 
General Procedure for Preparation of 2-4. A mixture of the corresponding amino-alcohol (2-amino-
1-ethanol, 2-amino-1-propanol or 2-amino-1-butanol, 10 mmol) and N-(7-chloro-4-quinolyl)-N-2-
[(1,1,1-trimethylammonio)methyl]ferrocenylmethylamine iodide recently prepared (0.41 mmol) was 
dissolved in acetonitrile (25 mL). Potassium carbonate (10 mmol) was added in excess, and the mixture 
was stirred for 3-7 h at reflux. After cooling to room temperature, the reaction was quenched with water 
(25 mL). The aqueous layer was then extracted with dichloromethane (3 × 50 mL). The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (EtOAc, 5% triethylamine). 
2-[(2-{[(7-chloro-4-quinolyl)amino]methyl}ferrocenylmethyl)amino]-1-ethanol (2). Following the 
general procedure, a yellow solid was obtained: yield 46 %; mp: decomposed before melting; 
1
H NMR 
(CDCl3)  8.41 (d, 1H, J = 5.5 Hz), 7.79 (d, 1H, J = 2.0 Hz), 7.68 (d, 1H, J = 9.1 Hz), 7.11 (dd, 1H, J = 
2.0, 9.8 Hz), 6.89 (m, 1H), 6.38 (d, 1H, J = 5.5 Hz), 4.28 (d, 1H, J = 13.0 Hz), 4.19 (m, 1H), 4.14 (m, 
1H), 4.09 (s, 5H), 4.03 (m, 2H), 3.67 (m, 3H), 3.49 (d, 1H, J = 12.4 Hz), 2.73 (m, 2H); 
13
C NMR 
(CDCl3)  150.7 (CH), 149.0 (C
IV
), 147.8 (C
IV
), 133.7 (C
IV
), 126.9 (CH), 123.7 (CH), 121.5 (CH), 
116.5 (C
IV
), 97.8 (CH), 84.3 (C
IV
), 82.2 (C
IV
), 69.5 (CH), 69.2 (CH), 68.2 (5CH), 65.4 (CH), 59.8 
(CH2), 50.1 (CH2), 46.6 (CH2), 41.1 (CH2); MS m/z 452 (MH
+
 
37
Cl), 451 (M
°+
 
37
Cl), 450 MH
+
 
35
Cl, 449 
(M
°+
 
35
Cl), 391 (M 
37
Cl – NHCH2CH2OH)
+
, 389 (M 
35
Cl – NHCH2CH2OH)
+
, 271 (M – NH2Q). 
2-[(2-{[(7-chloro-4-quinolyl)amino]methyl}ferrocenylmethyl)(methyl)amino]-1-ethanol (3). A 
yellow solid was obtained: yield 46 %; mp 164  1 °C; 1H NMR (CDCl3)  8.45 (d, 1H, J = 5.5 Hz), 
7.86 (d, 1H, J = 2.2 Hz), 7.71 (d, 1H, J = 8.9 Hz), 7.23 (d, 1H, J = 2.2 Hz), 6.77 (m, 1H), 6.46 (d, 1H, J 
= 5.5 Hz), 4.32 (m, 2H), 4.20 (m, 2H), 4.15 (s, 5H), 4.11 (m, 1H), 3.88 (d, 1H, J = 12.9 Hz), 3.67 (m, 
2H), 3.07 (d, 1H, J = 12.9 Hz), 2.74 (m, 1H), 2.48 (m, 1H), 2.19 (s, 3H); 
13
C NMR (CDCl3)  151.4 
(CH), 150.1 (C
IV
), 148.5 (C
IV
), 134.8 (C
IV
), 127.6 (CH), 124.8 (CH), 122.4 (CH), 117.4 (C
IV
), 98.8 
(CH), 84.0 (C
IV
), 83.8 (C
IV
), 71.5 (CH), 70.3 (CH), 69.3 (5CH), 66.4 (CH), 59.2 (CH2), 59.1 (CH2), 56.4 
(CH2), 42.4 (CH2), 41.9 (CH3); MS m/z 466 (MH
+
 
37
Cl), 465 (M
°+
 
37
Cl), 464 MH
+
 
35
Cl, 463 (M
°+
 
35
Cl), 
391 (M 
37
Cl – NHCH2CH2OH)
+
, 389 (M 
35
Cl – NHCH2CH2OH)
+
. 
2-[(2-{[(7-chloro-4-quinolyl)amino]methyl}ferrocenylmethyl)(ethyl)amino]-1-ethanol (4). A yellow 
solid was obtained: yield 51 %; mp 180  1 °C; 1H NMR (CDCl3)  8.43 (d, 1H, J = 5.5 Hz), 7.82 (d, 
1H, J = 2.1 Hz), 7.70 (d, 1H, J = 8.9 Hz), 7.21 (dd, 1H, J = 8.9, 2.1 Hz), 6.42 (d, 1H, J = 5.5 Hz), 4.25 
(m, 1H), 4.20 (s, 1H), 4.16 (m, 1H), 4.09 (s, 5H), 4.07 (m, 2H), 3.78 (d, 1H, J = 13.0 Hz), 3.50 (m, 2H), 
3.13 (d, 1H, J = 13.0 Hz), 2.71 (m, 1H), 2.58 (m, 1H), 2.40 (m, 2H), 0.88 (t, 3H, J = 7.2 Hz). 
13
C NMR 
(CDCl3)  151.2 (CH), 149.0 (C
IV
), 148.4 (C
IV
), 134.1 (C
IV
), 127.4 (CH), 124.3 (CH), 121.6 (CH), 
 8 
116.7 (C
IV
), 98.6 (CH), 83.8 (C
IV
), 82.9 (C
IV
), 70.9 (CH), 69.4 (CH), 68.6 (5CH), 65.9 (CH), 58.5 
(CH2), 53.8 (CH2), 51.8 (CH2), 47.2 (CH2), 40.9 (CH2), 10.1 (CH3); MS m/z 480 (MH
+
 
37
Cl), 479 (M
°+
 
37
Cl), 478 MH
+
 
35
Cl, 477 (M
°+
 
35
Cl), 391 (M 
37
Cl – NHCH2CH2OH)
+
, 389 (M 
35
Cl – NHCH2CH2OH)
+
. 
Antiviral evaluation, as described in ref. 25, 30, 31 and 32: ref. 25 as to SARS-CoV; ref. 30 as to 
HSV-1, HSV-2, vaccinia virus; ref. 31 as to various other RNA viruses; ref. 32 as to HIV-1. 
Antimalarial Activity. Laboratory Strains. The 3D7 and W2 strains of P. falciparum used as a 
control for sensitivity to CQ and FQ were cultured as previously described. Parasites were grown in 
vitro on O
+
 human red blood cells in RPMI 1640 medium (Invitrogen) supplemented with 10 % AB 
human serum (EFS), and 0.01 mg/ml gentamicin under an atmosphere of 90% nitrogen/ 5% oxygen/ 5% 
carbon dioxide. 
Field isolates. Isolates of P. falciparum were collected from 25 subjects recruited, for in vivo trials of 
mefloquine–artesunate, by the Cambodian Ministry of Health. All the subjects came from malaria-
endemic areas of Cambodia. Sampling and further treatment of samples were previously described.
33
 
All antimalarial measurements were done on fresh samples.  
For antimalarial activity measurements, a microplate assay measuring [
3
H] hypoxanthine incorporation 
in parasite nucleic acids and derived from the method of Desjardins
34
 was used to test FQ antimalarial 
properties on laboratory strains and Cambodian field isolates. Test procedures for laboratory strains 
were as previously described (0.5% hematocrit; 0.5% parasitaemia) (4, 5). IC50 were calculated from 
response curves by linear interpolation.  
Concerning field isolates, fresh blood samples were tested without prior culture adaptation. Erythrocyte 
suspensions (1.5% hematocrit; 0.1--1% parasitaemia) were cultivated as described above in an 
atmosphere enriched with 5% CO2. Ranges of concentrations were 5-5120 nM for CQ and FQ. Test 
microplates were incubated for 42-46h at 37 °C. Only assays showing at least a 10 fold increase in 
parasite counts between drug free control wells containing uninfected or infected red blood cells were 
considered for IC50 (Inhibitory concentration 50%) calculations which were done by log-probit 
approximation. 
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Figure 1. Chemical structure of chloroquine, hydroxychloroquine, and ferroquine. 
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Scheme 1. Synthesis of hydroxyferroquine derivatives 2-4. 
 
a
 (i) CH3I, acetone; (ii) HOCH2CH2NHR, CH3CN. 
 
 
Scheme 2. Proposed conversion of hydroxyferroquine derivatives to active metabolites, 2 , dMFQ and 
dEFQ. 
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Table 1. In vitro sensitivities of P. falciparum strains. 
cpd
a
 strain IC50, nM n IC90, nM n 
2 
3D7 
W2 
15.4 ± 5.5 
133.2 ± 7.4 
4 
3 
25.7 ± 7.1 
459.1 ± 53.3 
4 
3 
3 
3D7 
W2 
21.5 ± 14.5 
30 ± 8.8 
8 
3 
51.0 ± 22.2 
99.9 ± 5.3 
8 
3 
4 
3D7 
W2 
11.7 ± 5.7 
20.4 ± 1.1 
9 
3 
29.19 ± 17.9 
56 ± 1.9 
9 
3 
CQ 
3D7 
W2 
10.6 ± 5.6 
138.9 ± 20 
16 
11 
31 ± 16.5 
> 500 
16 
11 
MF 
3D7 
W2 
38.7 ± 5.3 
14.9 ± 0.4 
13 
4 
138.2 ± 29.7 
66.1 ± 24.3 
4 
3 
ARS 
3D7 
W2 
2.1 ± 0.3 
2.1 ± 0.2 
13 
4 
9.1 ± 5.1 
14 ± 1.6 
3 
4 
FQ 
3D7 
W2 
7.8 ± 2.9 
9.7 ± 2.4 
13 
4 
16.4 ± 9.4 
24.6 ± 4.6 
13 
4 
 
a 
CQ = chloroquine; MF = mefloquine; ARS = artesunate; FQ = ferroquine 
The results are expressed by the mean ± standard deviation of the mean. 
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Table 2. Comparison of the most active compound 4 with other antimalarials on Cambodian field 
isolates. 
cpd
a
 IC50, nM
b 
and range 
n Resistance
, % 
4 32.4 
(17.9-83.6) 
25 3.8 
CQ 191.8 
(80-538) 
25 92 
MF 25.2 
(1.4-106.5) 
23 56 
Q 146 
(50-827) 
25 3.8 
ARS 1.47 
(0.41-5.35) 
25 7.6 
FQ 22.94  
(11.7-83.6) 
25 3.8 
 
a 
CQ = chloroquine; MF = mefloquine; Q = quinine; ARS = artesunate; FQ = ferroquine 
b
 IC50 values are geometric means among isolates. 
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Table 3. Anti HIV-1 Activity, Cytotoxicity, and Selectivity Index in MT-4 Cells. 
cpd
a
 EC50, M
b
 CC50, M
c
 SI
d
 
2 > 2.3 > 2.3 - 
3 2.9 ± 1.1 9.1 ± 6.6 3 
4 10 > 10 - 
FQ > 2.4 > 2.4 - 
HCQ > 12 > 12 - 
CQ 8.86 ± 1.18 54.4 ± 23.9 6 
 
a 
FQ = ferroquine; CQ = chloroquine; HCQ = hydroxychloroquine 
b
 Effective concentration required to reduce HIV-1-induced cytopathic effect by 50% in MT-4 cells. 
c
 Cytotoxic concentration required to reduce MT-4 cell viability by 50%. 
d
 Selectivity index: ratio CC50/EC50. 
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Table 4. Anti-coronavirus activity 
cpd
a
 Feline coronavirus
b
 Human corona (SARS) virus
c
 
 EC50, M CC50, M EC50, M CC50, M SI
d
 
2 > 4 12 ± 0 4.9 ± 4.3 23 ± 15 4 
3  10 12 ± 0 1.9 ± 0.1 30 ± 3 16 
4 > 4 13 ± 0 3.6 ± 2.0 61 ± 1 17 
FQ 2.9 ± 1.2 12 ± 0 1.4 ± 0.1 20 ± 8.0 15 
HCQ 28 ± 27 84 ± 14 34 ± 5 >100 >3 
CQ >0.8 3.6 ± 0.3 6.5 ± 3.2 >100 >15 
 
a 
FQ = ferroquine; CQ = chloroquine; HCQ = hydroxychloroquine 
b
 Feline corona virus in Crandell-Reese feline kidney (CRFK) cells 
c 
SARS-coronavirus in Vero cells 
d
 Selectivity index(for SARS-coronavirus): ratio CC50/EC50. 
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